TaiRx, Inc.
6580
Rank in Stocks
#23876
TaiRx, Inc., established in 2011 and headquartered in Taipei City, Taiwan, is a... TaiRx, Inc., established in 2011 and headquartered in Taipei City, Taiwan, is a pharmaceutical company dedicated to the research, development, and commercialization of therapeutic solutions for cancer and other diseases. The company's clinical pipeline includes CVM-1118, an oral anti-cancer drug currently undergoing Phase II clinical trials, and Rexis, an add-on injection therapy for sepsis patients, which is in Phase III trials. In its pre-clinical stage, TaiRx is developing TRX-711 for secondary hyperparathyroidism, TRX-920 as an oral delivery formulation, and TRX-105, a molecule designed to treat and alleviate symptoms of various types of colitis. Beyond its developmental drugs, TaiRx also offers Zelnite, a medication that helps maintain patients' blood selenium levels and supports their immune systems. The company's future endeavors also involve the development of nodal diagnostic devices and innovative antibody-based drugs.
Share Price
$0.33837749
Last synced: 2026-11-10
Market Cap
$37.94M
Change (1 day)
0.00%
Change (1 year)
-55.28%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade TaiRx, Inc. (6580)
Category
Healthcare
EPS for TaiRx, Inc. (6580)
EPS as of June 2026 TTM: $-0.06
According to TaiRx, Inc.'s latest financial reports, its current EPS (TTM) is $-0.06. At the end of 2025 the company had an EPS of $-0.06, a decrease compared to its 2024 EPS of $-0.04.
EPS history for TaiRx, Inc. from 2013 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.06 | 7.50% |
| 2025 | $-0.06 | 65.89% |
| 2024 | $-0.04 | -49.00% |
| 2023 | $-0.08 | -2.59% |
| 2022 | $-0.08 | 55.22% |
| 2021 | $-0.05 | -41.00% |
| 2020 | $-0.08 | -29.84% |
| 2019 | $-0.12 | 8.48% |
| 2018 | $-0.11 | 55.98% |
| 2017 | $-0.07 | 19.50% |
| 2016 | $-0.06 | 30.48% |
| 2015 | $-0.05 | -6.17% |
| 2014 | $-0.05 | -50.31% |
| 2013 | $-0.10 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -24,379.07% |
US
|
|
| $-7.07 | 10,861.24% |
US
|
|
| $-5.29 | 8,101.55% |
AU
|
|
| $12.88 | -20,069.15% |
BE
|
|
| $21.56 | -33,526.36% |
NL
|
Questions about TaiRx, Inc.'s earnings per share (EPS)
What is TaiRx, Inc.'s earnings per share (EPS)?
TaiRx, Inc.'s earnings per share (EPS) over the last twelve months is $-0.06, as of Jun 2026.
What was TaiRx, Inc.'s earnings per share (EPS) in 2025?
In 2025, TaiRx, Inc.'s earnings per share (EPS) was $-0.06, compared with $-0.04 in 2024.
How has TaiRx, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, TaiRx, Inc.'s earnings per share (EPS) was highest in 2024 ($-0.04) and lowest in 2023 ($-0.08).
How does TaiRx, Inc.'s earnings per share (EPS) compare with similar companies?
TaiRx, Inc.'s earnings per share (EPS) ($-0.06) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.